Artificial intelligence (AI) software developer Sophia Genetics has added radiomics capabilities to its Sophia AI genomics analysis platform.
Based on mechanistic and mathematic modeling, the new radiomics capabilities can help predict how a tumor's size, volume, and location will evolve by analyzing quantitative image features from two or more consecutive imaging studies, according to the company.
Sophia said it has already executed clinical proofs of concept on hundreds of patient cases for lung and kidney cancer, glioma, and meningioma. The firm believes the technology will soon apply to any solid tumor.
